Amgen Inc. (AMGN) Institutional Ownership & Insider Trading

3,140 institutions reported holding Amgen Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 14 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AMGNAmgen Inc.Follow AMGN — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 237.5B
P/E TTM: 27.3
Dividend yield: 2.3%
52-week: —
Next earnings: 3 Nov, in 10 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

3,140 institutions held 82.7% of the shares. Across filers that reported both quarters, shares held changed +0.5%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	3,140	447	+0.5%	953	111	903	94
Mar 26	3,097	428	-0.5%	891	140	977	80
Dec 25	3,003	433	+0.4%	869	185	827	68
Sep 25	2,752	426	-0.7%	796	85	861	92
Jun 25	2,795	430	+0.6%	947	74	827	144
Mar 25	2,847	421	+2.4%	866	180	920	93
Dec 24	2,746	416	+0.7%	792	70	892	204
Sep 24	2,752	407	-4.3%	787	95	848	70

Amgen Inc. — questions

Who owns Amgen Inc. stock?: 3,140 institutions reported Amgen Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (9.1%), VANGUARD CAPITAL MANAGEMENT LLC (6.5%), STATE STREET CORP (5.7%).
Are Amgen Inc. insiders buying or selling?: 14 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Amgen Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.